Business Wire

NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence ...

BLACKSBURG, Va.--(BUSINESS WIRE)--NImmune Biopharma, (“NImmune”), a private late-clinical-stage precision immunology biopharmaceutical company focused on the discovery and development of best-in-class ...
Morningstar

Leading the Next Wave of Innovative IBD Therapeutics Targeting Immunometabolism: Josep Bassaganya-Riera Launches Clinical Program and Business Venture to Develop NIM-1324 for ...

Leading the Next Wave of Innovative IBD Therapeutics Targeting Immunometabolism: Josep Bassaganya-Riera Launches Clinical Program and Business Venture to Develop NIM-1324 for Ulcerative Colitis and ...
Business Wire

The NIMML Institute and NImmune Biopharma Announce Publication of Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, in Clinical ...

BLACKSBURG, Va.--(BUSINESS WIRE)--The NIMML Institute, (“NIMML”), a 501 (c)(3) nonprofit research institute dedicated to the discovery of novel precision medicines for infectious and autoimmune ...